Watch POAP mints live!

about 2 years ago

Loading

over 2 years ago

Loading

I have met Seema Bhat at DS&AI Madrid, May 2023

I collaborate with different functions to acquire, process and transform data using technologies for better insights and decision-making for Pharma R&D.​

over 2 years ago

I have met Seema Bhat at DS&AI Madrid, May 2023 POAP image

I had the honor of serving as the DSSS team's subject matter expert for Rave EDC and its integrations in the past. However, I now have the privilege of leading a diverse group of talented senior developers and user access management professionals within the DSSS team. By working together, we aim to deliver innovative solutions that optimize clinical trial performance and drive positive outcomes for our study teams.

over 2 years ago

I've met Rajesh Alluri at Bayer DS&AI F2F Meeting POAP image

I've met Christian Luginsland - Head of Business Excellence & Innovation, DS&AI F2F Event, Madrid 2023

#117402

2023-05-03

Thank you for being open and honest with feedback.

over 2 years ago

I've met Christian Luginsland - Head of Business Excellence & Innovation, DS&AI F2F Event, Madrid 2023 POAP image

I've met Friederike at Bayer's DS&AI Meeting in Madrid May 2023

I've met Friederike during the DS&AI meeting in May 2023 in Madrid. She works within Data Strategy and Governance in the group Proprietary Information Management.

over 2 years ago

I've met Friederike at Bayer's DS&AI Meeting in Madrid May 2023 POAP image

over 2 years ago

Loading

I am passionate about harnessing data and cutting-edge technologies to optimize the clinical impact of cancer drugs and diagnostics. Drawing from my personal experiences with cancer, I am devoted to developing analytical systems that integrate clinical, imaging, and biomarker data to provide real-time access to high-quality information. Throughout my career, I have worked closely with clinical teams, advocating for data-driven decision-making and uncovering insights into clinical realities. I strongly believe that by leveraging complex datasets, we can gain a deeper understanding of cancer biology, and subsequently improve our decision-making processes. This adaptable approach empowers us to address fundamental questions, such as which targets to pursue, which technologies to invest in, which drugs to prioritize, and ultimately, which therapies are best suited for individual patients.

over 2 years ago

I’ve met Dan Gusenleitner at Bayer's DS&AI F2F Madrid POAP image

over 2 years ago

Loading

over 2 years ago

Loading